Diabetic Ulcers Clinical Trial
Official title:
Sterile Wound Care Liquid Dressing in Treatment of Diabetic Ulcer in Necrosis Stable Stage: a Randomized Control Trial
This study aimed to investigate methods for promoting infection control, reducing tissue edema, and preventing excessive spread in diabetes foot ulcers in the necrosis stable stage. Additionally, it sought to explore potential indications for the use of aseptic wound care liquid dressings in these ulcers, with the goal of obtaining evidence-based medical data on their clinical efficacy. Participants will be assigned with a 1:1 ratio into intervention group and control group. Participants in the intervention group will be irrigated with sterile liquid dressing for each wound treatment on the basis of clinical standard treatment protocols for 2 weeks, until the end of the 2-week observation period. Participants in the control group will be irrigated with normal saline for each wound treatment for 2 weeks on the basis of the clinical standard diagnosis and treatment plan, until the end of the 2-week observation period.
Status | Not yet recruiting |
Enrollment | 28 |
Est. completion date | April 30, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, respiratory failure, renal failure etc., which have not been corrected. 2. Poor glycemic control; fasting blood glucose >15mmol/L; glycosylated hemoglobin >12%. 3. Active bleeding within the wound that prevents implementation of standard basic treatment protocols. 4. Serum albumin <20g/L; hemoglobin <60g/L; platelets <50×10^9/L 5. Advanced malignant tumor patients 6. Autoimmune disease activity period 7. History of allergy to aseptic wound care liquid dressing 8. Patient unable to cooperate or has mental disorders 9. Pregnant and lactating women 10. Eye injuries and natural cavities such as ear canal, nasal cavity or abdominal cavity 11. Skin tumors 12. Active skin diseases 13. According to the researcher's judgment, patients who clearly have factors affecting wound healing that cannot be removed are not suitable for this study or cannot comply with the requirements of this study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking University Third Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 2-week reduction rate of wound area | 2-week | ||
Secondary | 2-week wound healing rate | 2-week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05646121 -
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
|
||
Completed |
NCT03070925 -
Prospective PuraPly™ AM Case Series Study
|
N/A | |
Completed |
NCT01348581 -
Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing
|
N/A | |
Terminated |
NCT02148302 -
Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers
|
N/A | |
Withdrawn |
NCT02361437 -
Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers
|
N/A |